Home » Stocks » MEDS

Trxade Group, Inc. (MEDS)

Stock Price: $5.87 USD -0.11 (-1.84%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $5.95 +0.08 (1.36%) Jan 15, 7:46 PM
Market Cap 47.51M
Revenue (ttm) 16.82M
Net Income (ttm) -719,096
Shares Out 8.06M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE 17.64
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $5.87
Previous Close $5.98
Change ($) -0.11
Change (%) -1.84%
Day's Open 6.00
Day's Range 5.70 - 6.09
Day's Volume 116,644
52-Week Range 4.10 - 7.96


Hide News
GlobeNewsWire - 1 month ago

TAMPA, FL, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc. ( MEDS ) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the D...

24/7 Wall Street - 2 months ago

Trxade Group Inc. (NASDAQ: MEDS) shares jumped on Tuesday after the company announced that it entered into a definitive agreement with Amazon.com Inc.

Other stocks mentioned: AMZN
Market Watch - 2 months ago

Shares of Trxade Group Inc. soared 56% in active trading to pace all of the premarket's gainers Tuesday, after the online platform for pharmaceutical purchases announced a market program agree...

About MEDS

Trxade Group, together with its subsidiaries, owns and operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.co... [Read more...]

Pharmaceutical Retailers
IPO Date
Feb 13, 2020
Surendra K. Ajjarapu
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Trxade Group stock is "Buy." The 12-month stock price forecast is 12.17, which is an increase of 107.33% from the latest price.

Price Target
(107.33% upside)
Analyst Consensus: Buy